Journal Home
Search for

Articles in Press

Return to articles in press list

Enteropathy-associated T-cell lymphoma

Andrés J.M. FerreriabCorresponding Author Informationemail address, Pier Luigi Zinzanic, Silvia Goviab, Stefano A. Pilerid

Accepted 25 June 2010. published online 26 July 2010.
Corrected Proof

Abstract 

Enteropathy-associated T-cell lymphoma (EATL) is an intestinal tumour of intraepithelial T lymphocytes, usually presenting as a neoplasm composed of large lymphoid cells and often associated with necrosis and an inflammatory background, including large numbers of histiocytes and eosinophils. Intestinal intraepithelial α–β T-cells have been postulated as the normal-cell counterpart for EATL. EATL is the most common neoplastic complication of coeliac disease. The disease is uncommon in most parts of the world, but is seen with greater frequency in those areas with a high prevalence of coeliac disease, in particular Northern Europe. Usually, EATL occurs in adults, and generally present with abdominal pain, often associated with jejunal perforation, weight loss, diarrhoea, or bowel obstruction. EATL is characterized by multifocal presentation in 10–25% of cases. Small-bowel lymphoma is more common than large-bowel or rectal lymphomas. The prognosis of EATL is very poor, with low chemosensitivity, rapid tumour growth and a tendency to dissemination. Moreover, the high incidence of severe postsurgical complications and the poor nutritional and immunological conditions lead to progressive deterioration of these patients, preventing the use of an adequate and effective treatment.

a Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy

b Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy

c Clinical Unit, Department of Haematology and Oncological Sciences “L. and A. Seràgnoli”, Bologna University School of Medicine, Bologna, Italy

d Haematopathology Unit, Department of Haematology and Oncological Sciences “L. and A. Seràgnoli”, Bologna University School of Medicine, Bologna, Italy

Corresponding Author InformationCorresponding author at: Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. Tel.: +39 02 26437649; fax: +39 02 26437625.

PII: S1040-8428(10)00149-6

doi:10.1016/j.critrevonc.2010.06.006